- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00006100
Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma
A Phase I Pilot Trial to Evaluate the Toxicity of Epstein-Barr Virus Specific T-Lymphocytes or Peripheral Blood Mononuclear Cells for the Treatment of Relapsed/Refractory Hodgkin's Disease
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus may be effective treatment for Hodgkin's lymphoma.
PURPOSE: Phase I trial to study the effectiveness of allogeneic Epstein-Barr virus-specific cytotoxic T cells in treating patients who have progressive, relapsed, or refractory Hodgkin's lymphoma.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
OBJECTIVES:
- Determine the toxicity of allogeneic Epstein Barr virus (EBV)-specific cytotoxic T-lymphocytes (EBV CTL) in patients with progressive, relapsed, or refractory EBV-positive Hodgkin's lymphoma.
- Detect alterations in the anti-EBV cellular immunity of patients treated with EBV CTL.
OUTLINE: Donors undergo leukapheresis. Epstein Barr virus-specific cytotoxic T lymphocytes (EBV CTL) are cultured in vitro.
Patients receive an infusion of EBV CTL over 10 minutes on day 0. The EBV CTL infusion is preceded by 3 doses of fludarabine. Patients then receive interleukin-2 injections for 12 days after the EBV CTL infusion.
Patients are followed weekly for 1.5 months, twice a month for 1.5 months, and then monthly for 3 months.
PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study.
Undersøgelsestype
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
DISEASE CHARACTERISTICS:
Histologically proven Hodgkin's lymphoma
- Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation
- Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER)
Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria:
- EBV seropositive
- HIV negative
- HTLV-1 negative
- Hepatitis B surface antigen and hepatitis B core antibody IgM negative
- Hepatitis C antibody negative
- Must share at least 1 HLA haplotype with donor
PATIENT CHARACTERISTICS:
Age:
- 18 to 75
Performance status:
- Not specified
Life expectancy:
- At least 8 weeks
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin less than 2.0 mg/dL
SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)
- If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required
- No hepatic dysfunction causing moribundity
Renal:
- Creatinine clearance greater than 50 mL/min
- No renal dysfunction causing moribundity
Cardiovascular:
- No cardiac dysfunction causing moribundity
Pulmonary:
- No pulmonary dysfunction causing moribundity
Other:
- No neurologic dysfunction causing moribundity
- No history of severe transfusion reactions with blood products (including fetal calf serum)
- Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
Chemotherapy:
- See Disease Characteristics
- No concurrent antimetabolites
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
Surgery:
- Not specified
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studiestol: Kenneth G. Lucas, MD, Milton S. Hershey Medical Center
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Virussygdomme
- Infektioner
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesygdomme
- Immunproliferative lidelser
- DNA-virusinfektioner
- Tumorvirusinfektioner
- Herpesviridae infektioner
- Lymfom
- Epstein-Barr-virusinfektioner
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Anti-HIV-midler
- Anti-retrovirale midler
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Aldesleukin
- Fludarabin
- Fludarabin phosphat
Andre undersøgelses-id-numre
- CDR0000068109
- PSCI-2003-257
- UAB-0002
- NCI-G00-1829
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med aldesleukin
-
National Cancer Institute (NCI)AfsluttetMetastatisk melanom | NyrecellekræftForenede Stater
-
Cancer Biotherapy Research GroupUkendt
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI); Chiron CorporationAfsluttet
-
Blumenthal Cancer Center at Carolinas Medical CenterUkendt
-
Cancer Biotherapy Research GroupUkendtLungekræftForenede Stater
-
St. Anna KinderkrebsforschungUkendt
-
National Cancer Institute (NCI)Afsluttet
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)AfsluttetLymfomForenede Stater
-
University of Southern CaliforniaNational Cancer Institute (NCI)AfsluttetUspecificeret fast tumor hos voksne, protokolspecifikForenede Stater
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer InstituteAfsluttetMalignt melanomForenede Stater